Helus Pharma reports positive Phase 3 results for HLP003 in major depressive disorderNov 16Clinical readoutCybin Inc.
Helus Pharma finishes enrollment in Phase 3 MDD study, sets Q1 2027 GAD trial startNov 16Quarterly updateCybin Inc.
Helus Pharma to present Phase 3 APPROACH topline results for HLP003 on Nov 16Nov 16PublicationCybin Inc.
Cybin's Helus Pharma to join three investor conferences in New York in September 2026Sep 10PeopleCybin Inc.
Cybin files two Form D notices for equity awards to executives and directorsAug 19FinancingCybin Inc.
Helus Pharma completes enrollment in Phase 3 APPROACH study of HLP003 for MDDJul 21Trial updateCybin Inc.
Cybin's Helus Pharma reports FY2026 results, Phase 3 MDD trial past 88% enrollmentJun 29Quarterly updateCybin Inc.